Clinical Trial Search

Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg

Primary: Estimated Percentage of Participants in Blood Pressure Control at Baseline — 61; 59; 53; 64 % of particpants w/ controlled BP

Primary: Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo — -4.10; -11.3; -11.07; -5.63 mmHg

Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg

Primary: Blood Pressure — 135.36; 136.19; 89.67; 92.38 mmHG — p=0.006

Primary: Blood Pressure Control — 0; 0; 45.2; 71.8 percentage of participants

Primary: Adverse Events — 1; 1; 1; 1 participants

Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001

Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants

Primary: Number of Participants With Serious Adverse Events (SAEs) — 8 Participants

Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants

Primary: Blood Pressure — -10.1; -9.1 mm Hg — p=0.50

Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001

Primary: SBP — 130.2; 128.8 mm Hg

Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001

Primary: Number of Participants Screened — 12; 12 participants

Primary: Blood Pressure (Systolic) at 180 Days — 131; 131 mmHg — p=<0.001

Primary: Unadjusted and Adjusted Changes From Baseline in Systolic and Diastolic Blood Pressure at Weeks 1, 3, 6 — -1.2; -5.3; 0.8; -1.7 mmHg

Primary: Systolic Blood Pressure — 155.8; 154.3; 155.7; 150.4 mmHg

Primary: Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo — -15.22; -7.15 Millimeters of mercury (mmHg) — p=0.003

Primary: Number of Participants Whose Blood Pressure Was Assessed in the First Ten Days Following Discharge — 45; 95 Participants

Primary: Change From Baseline in Mean Seated Systolic BP (SBP) — -16.6; -17.0; -16.0; -19.8 mmHg

Primary: Performance of Blood Pressure Referral Threshold — .841 proportion

Primary: In-clinic Blood Pressure Change — 136.0; 140.3; 126.9; 136.1 mm Hg — p=0.72

Primary: Blood Pressure Change — 148; 147; 79; 79 mmHg

Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) — -8.7; -3.6 mmHg — p=<.001

Primary: Percentage of Patient Visits With Completion of Out-of-office BP Monitoring Within 6 Months of an Eligible Visit During the Pre-Implementation Period — 0.6; 5.4…

Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants